WhatsApp
backNews Article

Bafna Pharmaceuticals Posts INR 692.33 Lakh Profit Before Tax in Q2 2026 Unaudited Results

Company reports total income of INR 4,879.97 lakh and shares assets and liabilities details as of September 30, 2026

Bafna Pharmaceuticals Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026, reporting profit before tax of INR 692.33 lakh for the quarter. The results include a total income of INR 4,879.97 lakh for the quarter and highlight key financial positions as of September 30, 2026, supported by a limited review report from statutory auditors.

11 Nov 2026|BAFNAPH+1.15%
Bafna Pharmaceuticals Limited532989BAFNAPHFinancial Results

Bafna Pharmaceuticals Limited

Financial Results

Bafna Pharmaceuticals Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026, posting a profit before tax of INR 692.33 lakh for the quarter. These results were reviewed by the audit committee and accompanied by a limited review report from the statutory auditors.

The company reported total income for the quarter of INR 4,879.97 lakh, including revenue from operations of INR 4,766.56 lakh and other income of INR 113.41 lakh.

Total expenses for the quarter were INR 4,821.91 lakh, resulting in a profit before exceptional items and tax of INR 7.51 lakh, improving to INR 692.33 lakh after adjustments for costs within the quarter.

As of September 30, 2026, Bafna Pharmaceuticals held total assets valued at INR 19,300.29 lakh, with equity of INR 10,319.44 lakh. Non-current assets mainly consist of property, plant, and equipment valued at INR 8,803.62 lakh.

The company stated ongoing legal matters concerning Goods and Services Tax (GST) claims amounting to INR 566.56 lakh and reported confidence in prevailing against these claims based on current legal positions and practices.

The unaudited results have been prepared according to Indian Accounting Standards (Ind AS 34) and reviewed by the statutory auditors through limited review in compliance with SEBI regulations.

Highlights

  • Profit before tax of INR 692.33 lakh reported for quarter ended September 30, 2026.
  • Total income for the quarter: INR 4,879.97 lakh.
  • Equity share capital remains at INR 2,365.63 lakh with other equity at INR 7,953.81 lakh as of September 30, 2026.
  • Total assets recorded at INR 19,300.29 lakh, reflecting the company's financial position at period end.
  • Company continuing legal appeals regarding GST liabilities totaling over INR 566 lakh with associated stay orders obtained.

Key Data Snapshot

Profit before tax for quarter ended September 30, 2026INR 692.33 lakh
Total income for quarter ended September 30, 2026INR 4,879.97 lakh
Revenue from operations for quarter ended September 30, 2026INR 4,766.56 lakh
Total assets as at September 30, 2026INR 19,300.29 lakh
Equity share capital as at September 30, 2026INR 2,365.63 lakh
Other equity as at September 30, 2026INR 7,953.81 lakh
Non-current assets as at September 30, 2026INR 9,116.68 lakh

Financial performance

  • The company earned revenue from operations of INR 4,766.56 lakh and other income of INR 113.41 lakh during Q2 2026.
  • Total expenses amounted to INR 4,821.91 lakh including costs of materials, manufacturing, employee benefits, finance costs, and depreciation.
  • Profit before tax for the quarter was INR 692.33 lakh after accounting for income and expenses.
  • Earnings per share (basic and diluted) for the quarter stood at INR 2.89.
  • Comprehensive income for the quarter totaled INR 690.90 lakh.

Key details

  • Unaudited financial results for Q2 and H1 ended September 30, 2026, approved by the Board on November 11, 2026.
  • Results reviewed by the Audit Committee and statutory auditors issued a limited review report.
  • Company prepared the results under Ind AS 34 in compliance with Indian accounting standards and SEBI regulations.
  • Reported GST-related claims of INR 235.47 lakh and INR 331.09 lakh are under legal appeal or stay, with confidence to prevail against GST authorities.
  • Board meeting was held from 2:35 PM to 3:50 PM on November 11, 2026, to approve these results.

Background and context

  • Bafna Pharmaceuticals operates in the pharmaceutical formulation manufacturing segment, considered a single business segment under Ind AS 108.
  • The company maintains its registered and corporate office in Chennai, India.
  • The financial results reflect ongoing business operations including production, sales, and associated costs for the reported periods.
  • Company adheres to regulations under SEBI (Listing Obligations and Disclosure Requirements) and Indian Companies Act for disclosures.

More News on Financial Results

View all

Latest corporate announcements and market updates in Financial Results.

View all news
Bafna Pharmaceuticals Posts INR 692.33 Lakh Profit | Stockk News